Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Accumulated Expenses (2022 - 2025)

Entrada Therapeutics has reported Accumulated Expenses over the past 4 years, most recently at $17.7 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $17.7 million for Q4 2025, up 32.52% from a year ago — trailing twelve months through Dec 2025 was $17.7 million (up 32.52% YoY), and the annual figure for FY2025 was $17.7 million, up 32.52%.
  • Accumulated Expenses for Q4 2025 was $17.7 million at Entrada Therapeutics, up from $15.5 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for TRDA hit a ceiling of $17.7 million in Q4 2025 and a floor of $4.5 million in Q1 2022.
  • Median Accumulated Expenses over the past 4 years was $11.2 million (2023), compared with a mean of $10.5 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 158.09% in 2023 and later dropped 24.7% in 2024.
  • Entrada Therapeutics' Accumulated Expenses stood at $7.6 million in 2022, then soared by 49.49% to $11.3 million in 2023, then increased by 17.82% to $13.3 million in 2024, then surged by 32.52% to $17.7 million in 2025.
  • The last three reported values for Accumulated Expenses were $17.7 million (Q4 2025), $15.5 million (Q3 2025), and $11.8 million (Q2 2025) per Business Quant data.